Trial Timelines & Delay Analysis
Where trials slip — and how much value the slip costs.
A structured approach to analyzing clinical-trial timelines and delay drivers — for portfolio risk, BD valuation and operational planning.
"How much timeline risk should we discount this asset for?"
Average trial delay is 6–12 months at Phase 3. Recruitment, manufacturing and protocol amendments are the largest drivers. Each month of delay costs measurable NPV — model it.
Trial delay is the single most under-modeled variable in pharma portfolio strategy. The right approach makes it visible: TA-specific delay distributions, per-asset risk scoring, and continuous monitoring of operational milestones.
Translate delays into NPV
Delay × NPV per month per asset = the real cost. With that number on the table, BD and R&D leadership prioritize operational interventions that pay back in months.
What we’re seeing in the data.
Recruitment is the #1 delay driver
Patient recruitment underperforms plan in 40%+ of trials.
Manufacturing causes ATMP slips
Cell, gene and ADC trials face material manufacturing-related delays.
Protocol amendments compound
Each amendment adds weeks; multiple amendments can add quarters.
Site activation lag
Site activation is the most under-forecasted operational variable.
How to think about it.
-
01
Map historical delay distribution
TA, modality, sponsor, geography.
-
02
Score per-trial risk
Recruitment plan vs site footprint, comparator availability.
-
03
Apply to PoS-weighted forecast
Delay × NPV per month = real cost.
-
04
Forecast operational interventions
Decentralized trial, AI site selection, adaptive design.
-
05
Track in real-time
Site enrollment dashboards, milestone monitoring.
What separates a good answer from a defensible one.
EM trial sites can recruit faster but face regulatory complexity.
Active-comparator trials face supply-chain delays.
Reduces sample-size risk but can extend duration.
DCT can speed recruitment but introduces new operational risk.
Where the signal comes from.
Common questions.
How much does a 6-month delay cost?
For a $1B peak-sales asset, often $50–150M of NPV — depending on competitor density.
Can AI reduce trial delay risk?
Yes — site-selection, recruitment-prediction and protocol-amendment AI tools have demonstrated 10–30% delay reduction in real programs.
Want this answered on your data?
We build decision systems on top of analyses like this — so the next question takes minutes, not weeks.
Talk to a strategist